Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455677 | 0.87 | FLT3 (0.74) | FLT3KMT2AMEN1RECQLALDH1A1 | |
| SCHEMBL5447330 | 0.86 | FLT3 (0.47) | FLT3KMT2AMEN1RECQLRAB9A | |
| SCHEMBL20704813 | 0.86 | FLT3 (0.80) | FLT3KMT2AMEN1RECQLALDH1A1 | |
| SCHEMBL5462904 | 0.85 | CFTR (0.54) | FLT3KMT2AMEN1RECQLRAB9A | |
| SCHEMBL8289827 | 0.83 | KMT2A (0.82) | FLT3KMT2AMEN1RECQLALDH1A1 | |
| SCHEMBL5449715 | 0.82 | PTPN1 (0.48) | FLT3KMT2AMEN1RECQLRAB9A | |
| SCHEMBL5455906 | 0.82 | FLT3 (0.74) | FLT3KMT2AMEN1RECQLALDH1A1 | |
| SCHEMBL5455531 | 0.82 | FLT3 (0.61) | FLT3KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL5446246 | 0.81 | FLT3 (0.73) | FLT3KMT2AMEN1RECQLALDH1A1 | |
| SCHEMBL20704747 | 0.81 | ALOX15 (0.60) | FLT3KMT2AMEN1RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885KMT2A 4785/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.